Jupiter Neurosciences, Inc., a clinical-stage biotech firm based in Florida, has announced the launch of Nugevia, a consumer-facing longevity and performance supplement line grounded in clinical research. The company said that the new product line is derived from its proprietary compound JOTROL™, which has been under clinical development for neurological and age-related conditions.
The initial product range includes three offerings—Neuro, Neuro Plus, and Vitality—formulated to support cognitive health, energy, inflammation response, and overall performance. According to the company, Nugevia products feature a nano-formulated, lipophilic resveratrol designed to increase absorption and bioavailability.
“Unlike other longevity products in the market, Nugevia is backed by peer-reviewed science and pre-clinical research,” the company said. Jupiter Neurosciences claims the supplement line benefits from the same active ingredient used in its investigational new drug JOTROL™, currently in Phase 2 trials for mild cognitive impairment in Alzheimer’s disease.
Each capsule reportedly delivers more than 90% absorption of the active compound, a significant increase over traditional resveratrol supplements. The company also emphasized that Nugevia is manufactured in the U.S. and available exclusively through its new e-commerce platform.
CEO and Chairman Joseph Maroon stated that the launch of Nugevia marks “a significant milestone” in making clinical-grade science available to consumers. The company plans to expand distribution beyond direct-to-consumer channels in the future.
